Transforming growth factor-β regulation of immune responses

Annual Review of Immunology

Volumn 24, Issue , 2006, Pages 99-146

  Li, Ming O ^a   Wan, Yisong Y ^a   Sanjabi, Shomyseh ^a   Robertson, Anna Karin L ^a   Flavell, Richard A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunopathology; Inflammation; Smad; TGF ; Tolerance

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN A; LATENCY ASSOCIATED PEPTIDE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANTIGEN PRESENTATION; ASTHMA; AUTOIMMUNITY; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMOTAXIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA VIRUS; ENTERITIS; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRANULOCYTE; HELPER CELL; HUMAN; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFECTION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LEISHMANIASIS; LISTERIOSIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALARIA; MAST CELL; MONOCYTE; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; MYCOSIS; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTOZOON; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RNA VIRUS; SIGNAL TRANSDUCTION; TH1 CELL; TRYPANOSOMIASIS; TUMOR IMMUNITY; VIRUS INFECTION; WOUND HEALING;

ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELLS; GRANULOCYTES; HUMANS; IMMUNOGLOBULIN A; INFECTION; KILLER CELLS, NATURAL; MACROPHAGES; MAST CELLS; MODELS, IMMUNOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33646164362     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.24.021605.090737     Document Type: Review

References (377)

1. Kappler JW, Roehm N, Marrack P. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273-80
2. Goodnow CC, Cyster JG, Hartley SB, Bell SE, Cooke MP, et al. 1995. Self-tolerance checkpoints in B lymphocyte development. Adv. Immunol. 59:279-368
3. Medzhitov R, Janeway CA Jr. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91:295-98
4. Guerder S, Picarella DE, Linsley PS, Flavell RA. 1994. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor α leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA 91:5138-42
5. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, et al. 2001. An essential role of the NF-κB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166:7128-35
6. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603-7
7. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-62
8. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765
9. Letterio JJ, Roberts AB. 1998. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16:137-61
10. Wahl SM. 1994. Transforming growth factor β: the good, the bad, and the ugly. J. Exp. Med. 180:1587-90
11. Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor β in human disease. N. Engl. J. Med. 342:1350-58
12. Newfeld SJ, Wisotzkey RG, Kumar S. 1999. Molecular evolution of a developmental pathway: phylogenetic analyses of transforming growth factor-β family ligands, receptors and Smad signal transducers. Genetics 152:783-95
13. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, et al. 1986. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163:1037-50
14. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, et al. 1992. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359:693-99
15. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, et al. 1993. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90:770-74
16. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, et al. 1999. Targeted disruption of SMAD 3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J. 18:1280-91
17. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, et al. 1999. Targeted disruption of Smad 3 reveals an essential role in transforming growth factor β-mediated signal transduction. Mol. Cell. Biol. 19:2495-504
18. Gorelik L, Flavell RA. 2000. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12:171-81
19. Lucas PJ, Kim SJ, Melby SJ, Gress RE. 2000. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor β II receptor. J. Exp. Med. 191:1187-96
20. Nakao A, Miike S, Hatano M, Okumura K, Tokuhisa T, et al. 2000. Blockade of transforming growth factor β/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J. Exp. Med. 192:151-58
21. Cazac BB, Roes J. 2000. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13:443-51
22. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. 2005. Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ. Nat. Immunol. 6:600-7
23. Chang H, Brown CW, Matzuk MM. 2002. Genetic analysis of the mammalian transforming growth factor-β superfamily. Endocr. Rev. 23:787-823
24. Govinden R, Bhoola KD. 2003. Genealogy, expression, and cellular function of transforming growth factor-β. Pharmacol. Ther. 98:257-65
25. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R. 1995. Processing of transforming growth factor β1 precursor by human furin convertase. J. Biol. Chem. 270:10618-24
26. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGF β activation. J. Cell Sci. 116:217-24
27. Nunes I, Shapiro RL, Rifkin DB. 1995. Characterization of latent TGF-β activation by murine peritoneal macrophages. J. Immunol. 155:1450-59
28. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, et al. 1998. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93:1159-70
29. Yehualaeshet T, O'Connor R, Green-Johnson J, Mai S, Silverstein R, et al. 1999. Activation of rat alveolar macrophage-derived latent transforming growth factor β-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am. J. Pathol. 155:841-51
30. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, et al. 1999. The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-28
31. Annes JP, Chen Y, Munger JS, Rifkin DB. 2004. Integrin αVβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1. J. Cell Biol. 165:723-34
32. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. 1988. Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J. Biol. Chem. 263:7741-46
33. Kim SJ, Jeang KT, Glick AB, Sporn MB, Roberts AB. 1989. Promoter sequences of the human transforming growth factor-β1 gene responsive to transforming growth factor-β1 autoinduction. J. Biol. Chem. 264:7041-45
34. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, et al. 1990. Autoinduction of transforming growth factor β1 is mediated by the AP-1 complex. Mol. Cell. Biol. 10:1492-97
35. Ventura JJ, Kennedy NJ, Flavell RA, Davis RJ. 2004. JNK regulates autocrine expression of TGF-β1. Mol. Cell 15:269-78
36. Kim SJ, Park K, Koeller D, Kim KY, Wakefield LM, et al. 1992. Post-transcriptional regulation of the human transforming growth factor-β1 gene. J. Biol. Chem. 267:13702-7
37. Allison RS, Mumy ML, Wakefield LM. 1998. Translational control elements in the major human transforming growth factor-β1 mRNA. Growth Factors 16:89-100
38. Roberts AB, Sporn MB. 1992. Differential expression of the TGF-β1 isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol. Reprod. Dev. 32:91-98
39. Brown CB, Boyer AS, Runyan RB, Barnett JV. 1999. Requirement of type III TGF-β receptor for endocardial cell transformation in the heart. Science 283:2080-82
40. Massague J. 1998. TGF-β signal transduction. Annu. Rev. Biochem. 67:753-91
41. ten Dijke P, Hill CS. 2004. New insights into TGF-β-Smad signalling. Trends Biochem. Sci. 29:265-73
42. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. 2001. The TGF β receptor activation process: an inhibitor- to substrate-binding switch. Mol. Cell 8:671-82
43. Inman GJ, Nicolas FJ, Hill CS. 2002. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-β receptor activity. Mol. Cell 10:283-94
44. Johnson K, Kirkpatrick H, Comer A, Hoffmann FM, Laughon A. 1999. Interaction of Smad complexes with tripartite DNA-binding sites. J. Biol. Chem. 274:20709-16
45. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. 1998. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-β signaling. Cell 94:585-94
46. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, et al. 1998. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1:611-67
47. Liu F, Pouponnot C, Massague J. 1997. Dual role of the Smad4/DPC4 tumor suppressor in TGFβ-inducible transcriptional complexes. Genes Dev. 11:3157-67
48. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, et al. 1997. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 389:631-35
49. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, et al. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF β receptor for degradation. Mol. Cell 6:1365-75
50. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, et al. 2001. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276:12477-80
51. Attisano I., Wrana JL. 2000. Smads as transcriptional co-modulators. Curr. Opin. Cell Biol. 12:235-43
52. Massague J, Wotton D. 2000. Transcriptional control by the TGF-β/Smad signaling system. EMBO J. 19:1745-54
53. ten Dijke P, Miyazono K, Heldin CH. 2000. Signaling inputs converge on nuclear effectors in TGF-β signaling. Trends Biochem. Sci. 25:64-70
54. Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577-84
55. Shi Y, Massague J. 2003. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113:685-700
56. Engel ME, McDonnell MA, Law BK, Moses HL. 1999. Interdependent SMAD and JNK signaling in transforming growth factor-β-mediated transcription. J. Biol. Chem. 274:37413-20
57. Yu L, Hebert MC, Zhang YE. 2002. TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J. 21:3749-59
58. Kretzschmar M, Doody J, Timokhina I, Massague J. 1999. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev. 13:804-16
59. Funaba M, Zimmerman CM, Mathews LS. 2002. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J. Biol. Chem. 277:41361-68
60. Blanchette F, Rivard N, Rudd P, Grondin F, Attisano L, Dubois CM. 2001. Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor β1-induced furin gene transactivation. J. Biol. Chem. 276:33986-94
61. Choy L, Derynck R. 1998. The type II transforming growth factor (TGF)-β receptor-interacting protein TRIP-1 acts as a modulator of the TGF-β response. J. Biol. Chem. 273:31455-62
62. McGonigle S, Beall MJ, Pearce EJ. 2002. Eukaryotic initiation factor 2α subunit associates with TGFβ receptors and 14-3-3ε and acts as a modulator of the TGFβ response. Biochemistry 41:579-87
63. Griswold-Prenner I, Kamibayashi C, Maruoka EM, Mumby MC, Derynck R. 1998. Physical and functional interactions between type I transforming growth factor β receptors and Bα, a WD-40 repeat subunit of phosphatase 2A. Mol. Cell. Biol. 18:6595-604
64. Gorelik L, Flavell RA. 2002. Transforming growth factor-β in T-cell biology. Nat. Rev. Immunol. 2:46-53
65. Cerwenka A, Swain SL. 1999. TGF-β1: immunosuppressant and viability factor for T lymphocytes. Microbes Infect. 1:1291-96
66. Brabletz T, Pfeuffer I, Schorr E, Siebelt F, Wirth T, Serfling E. 1993. Transforming growth factor β and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol. Cell. Biol. 13:1155-62
67. McKarns SC, Schwartz RH, Kaminski NE. 2004. Smad3 is essential for TGF-β1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J. Immunol. 172:4275-84
68. Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, et al. 2001. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat. Immunol. 2:1174-82
69. Hannon GJ, Beach D. 1994. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-61
70. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. 1995. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 92:5545-49
71. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, et al. 1994. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22
72. Coffey RJ Jr, Bascom CC, Sipes NJ, Graves-Deal R, Weissman BE, et al. 1988. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor β. Mol. Cell. Biol. 8:3088-93
73. Wolfraim LA, Walz TM, James Z, Fernandez T, Letterio JJ. 2004. p21Cip1 and p27Kip1 act in synergy to alter the sensitivity of naive T cells to TGF-β-mediated G1 arrest through modulation of IL-2 responsiveness. J. Immunol. 173:3093-102
74. Ruegemer JJ, Ho SN, Augustine JA, Schlager JW, Bell MP, et al. 1990. Regulatory effects of transforming growth factor-β on IL-2- and IL-4-dependent T cell-cycle progression. J. Immunol. 144:1767-76
75. Genestier L, Kasibhatla S, Brunner T, Green DR. 1999. Transforming growth factor β1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J. Exp. Med. 189:231-39
76. Nelson BH, Martyak TP, Thompson LJ, Moon JJ, Wang T. 2003. Uncoupling of promitogenic and antiapoptotic functions of IL-2 by Smad-dependent TGF-β signaling. J. Immunol. 170:5563-70
77. + T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3. J. Immunol. 174:2071-83
78. Cottrez F, Groux H. 2001. Regulation of TGF-β response during T cell activation is modulated by IL-10. J. Immunol. 167:773-78
79. + T cells. Int. Immunol. 3:233-45
80. 2+-calcineurin-mediated activation in thymocytes. J. Immunol. 170:3645-52
81. + T cell tumorigenesis. Cancer Res. 64:6524-29
82. Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, et al. 2004. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N. Engl. J. Med. 351:552-59
83. Murphy KM, Reiner SL. 2002. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2:933-44
84. Sad S, Mosmann TR. 1994. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J. Immunol. 153:3514-22
85. Gorelik L, Fields PE, Flavell RA. 2000. Cutting edge: TGF-β inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 165:4773-77
86. Heath VL, Murphy EE, Crain C, Tomlinson MG, O'Garra A. 2000. TGF-β1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression. Eur. J. Immunol. 30:2639-49
87. 2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J. Exp. Med. 197:1689-99
88. Gorham JD, Guler ML, Fenoglio D, Gubler U, Murphy KM. 1998. Low dose TGF-β attenuates IL-12 responsiveness in murine Th cells. J. Immunol. 161:1664-70
89. Gorelik L, Constant S, Flavell RA. 2002. Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195:1499-505
90. + T cells. Nat. Immunol. 3:549-57
91. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655-69
92. + T cells at priming and at recall: differential involvement of Stat4 and T-bet. J. Immunol. 174:5950-58
93. + Th1/Th2 T cells. Eur. J. Immunol. 30:2101-11
94. Ulloa L, Doody J, Massague J. 1999. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature 397:710-13
95. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. 2003. Transforming growth factor (TGF)-β1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-β1-mediated fibrosis. J. Exp. Med. 198:1179-88
96. Fuss IJ, Boirivant M, Lacy B, Strober W. 2002. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J. Immunol. 168:900-8
97. + T cells depends on IL-2, is synergistically enhanced by a combination of TGF-β and IL-4, and is inhibited by IFN-γ. J. Immunol. 153:3989-96
98. + T cells. J. Immunol. 170:4785-92
99. Letterio JJ, Geiser AG, Kulkarni AB, Dang H, Kong L, et al. 1996. Autoimmunity associated with TGF-β1-deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Invest. 98:2109-19
100. + effector and memory T cell generation. Nat. Immunol. 4:835-42
101. Ranges GE, Figari IS, Espevik T, Palladino MA Jr. 1987. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166:991-98
102. + T lymphocytes. Inhibition by transforming growth factor-β. J. Immunol. 146:3289-97
103. Bonig H, Banning U, Hannen M, Kim YM, Verheyen J, et al. 1999. Transforming growth factor-β1 suppresses interleukin-15-mediated interferon-γ production in human T lymphocytes. Sound. J. Immunol. 50:612-18
104. Ahmadzadeh M, Rosenberg SA. 2005. TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J. Immunol. 174:5215-23
105. Glimcher LH, Townsend MJ, Sullivan BM, Lord GM. 2004. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4:900-11
106. Croft M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3:609-20
107. + T-cell effector differentiation by TGF-β1 and 4-1BB costimulation. Blood 105:274-81
108. 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-β1 null mouse. J. Immunol. 163:4013-19
109. Gorelik L, Flavell RA. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 7:1118-22
110. Gershon RK. 1975. A disquisition on suppressor T cells. Transplant Rev. 26:170-85
111. Fontenot JD, Rudensky AY. 2005. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6:331-37
112. - CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc. Natl. Acad. Sci. USA 102:4091-96
113. + regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201:127-37
114. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265:1237-40
115. + regulatory T cell subsets. J. Leukoc. Biol. 74:471-78
116. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198:1875-86
117. - T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172:5149-53
118. - cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J. Immunol. 172:5213-21
119. Wan YY, Flavell RA. 2005. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc. Natl. Acad. Sci. USA 102:5126-31
120. + regulatory T cells responsible for protection against diabetes. Proc. Natl. Acad. Sci. USA 101:4572-77
121. + T cells. J. Immunol. 173:6526-31
122. + regulatory T cells. J. Exp. Med. 201:1061-67
123. + regulatory T cells independent of autocrine TGF-β1. Blood 103:4594-601
124. + regulatory T cells. J. Exp. Med. 201:737-46
125. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. 2005. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 22:329-41
126. Green DR, Droin N, Pinkoski M. 2003. Activation-induced cell death in T cells. Immunol. Rev. 193:70-81
127. Marrack P, Kappler J. 2004. Control of T cell viability. Annu. Rev. Immunol. 22:765-87
128. + naive human T-cells. Int. Immunol. 17:35-44
129. Swain SL, Huston G, Tonkonogy S, Weinberg A. 1991. Transforming growth factor-β and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol. 147:2991-3000
130. Weinberg AD, Whitham R, Swain SL, Morrison WJ, Wyrick G, et al. 1992. Transforming growth factor-β enhances the in vivo effector function and memory phenotype of antigen-specific T helper cells in experimental autoimmune encephalomyelitis. J. Immunol. 148:2109-17
131. + T lymphocytes. Int. Immunol. 6:631-38
132. Zhang X, Giangreco L, Broome HE, Dargan CM, Swain SL. 1995. Control of CD4 effector fate: transforming growth factor β1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J. Exp. Med. 182:699-709
133. Swain SL, Croft M, Dubey C, Haynes L, Rogers P, et al. 1996. From naive to memory T cells. Immunol. Rev. 150:143-67
134. + T cell growth and apoptosis. J. Immunol. 157:2916-23
135. Cerwenka A, Kovar H, Majdic O, Holter W. 1996. Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-β1. J. Immunol. 156:459-64
136. Chen W, Jin W, Tian H, Sicurello P, Frank M, et al. 2001. Requirement for transforming growth factor β1 in controlling T cell apoptosis. J. Exp. Med. 194:439-53
137. Bommireddy R, Saxena V, Ormsby I, Yin M, Boivin GP, et al. 2003. TGF-β1 regulates lymphocyte homeostasis by preventing activation and subsequent apoptosis of peripheral lymphocytes. J. Immunol. 170:4612-22
138. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. 2002. Interferon γ is required for activation-induced death of T lymphocytes. J. Exp. Med. 196:999-1005
139. Weiner HL. 2001. Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunol. Rev. 182:207-14
140. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194:629-44
141. high-induced colitis by a TGF-β-dependent mechanism. J. Immunol. 170:2516-22
142. + T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes. Proc. Natl. Acad. Sci. USA 100:10878-83
143. + regulatory T cells can mediate suppressor function in the absence of transforming growth factor β1 production and responsiveness. J. Exp. Med. 196:237-46
144. + T cells. J. Exp. Med. 183:2669-74
145. + regulatory T cell activity in both humans and mice. J. Immunol. 172:834-42
146. + T cells. J. Exp. Med. 188:1849-57
147. Gomes NA, Gattass CR, Barreto-De-Souza V, Wilson ME, DosReis GA. 2000. TGF-β mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J. Immunol. 164:2001-8
148. Kitani A, Chua K, Nakamura K, Strober W. 2000. Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J. Immunol. 165:691-702
149. Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, et al. 2001. Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proc. Natl. Acad. Sci. USA 98:2587-92
150. Esplugues E, Sancho D, Vega-Ramos J, Martinez C, Syrbe U, et al. 2003. Enhanced antitumor immunity in mice deficient in CD69. J. Exp. Med. 197:1093-106
151. Sancho D, Gomez M, Viedma F, Esplugues E, Gordon-Alonso M, et al. 2003. CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J. Clin. Invest. 112:872-82
152. + T cells: IL-4 and IFN-γ have opposing effects, while TGF-β positively regulates its own production. J. Immunol. 160:5719-28
153. Neurath MF, Weigmann B, Finotto S, Glickman J, Nieuwenhuis E, et al. 2002. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195:1129-43
154. Chen W, Frank ME, Jin W, Wahl SM. 2001. TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14:715-25
155. Stavnezer J. 1995. Regulation of antibody production and class switching by TGF-β. J. Immunol. 155:1647-51
156. Lebman DA, Edmiston JS. 1999. The role of TGF-β in growth, differentiation, and maturation of B lymphocytes. Microbes Infect. 1:1297-304
157. Kee BL, Rivera RR, Murre C. 2001. Id3 inhibits B lymphocyte progenitor growth and survival in response to TGF-β. Nat. Immunol. 2:242-47
158. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. 1986. Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 137:3855-60
159. Petit-Koskas E, Genot E, Lawrence D, Kolb JP. 1988. Inhibition of the proliferative response of human B lymphocytes to B cell growth factor by transforming growth factor-β. Eur. J. Immunol. 18:111-16
160. 1 to S transition, but not activation of human B lymphocytes. Exp. Cell Res. 171:213-22
161. Bouchard C, Fridman WH, Sautes C. 1997. Effect of TGF-β1 on cell cycle regulatory proteins in LPS-stimulated normal mouse B lymphocytes. J. Immunol. 159:4155-64
162. Kamesaki H, Nishizawa K, Michaud GY, Cossman J, Kiyono T. 1998. TGF-β1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells. J. Immunol. 160:770-77
163. Roes J, Choi BK, Cazac BB. 2003. Redirection of B cell responsiveness by transforming growth factor β receptor. Proc. Natl. Acad. Sci. USA 100:7241-46
164. Patil S, Wildey GM, Brown TL, Choy L, Derynck R, Howe PH. 2000. Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-β-induced growth inhibition and apoptosis. J. Biol. Chem. 275:38363-70
165. Briskin M, Kuwabara MD, Sigman DS, Wall R. 1988. Induction of κ transcription by interferon-γ without activation of NF-κB. Science 242:1036-37
166. Kehrl JH, Thevenin C, Rieckmann P, Fauci AS. 1991. Transforming growth factor-β suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J. Immunol. 146:4016-23
167. Lebman DA, Lee FD, Coffman RL. 1990. Mechanism for transforming growth factor β and IL-2 enhancement of IgA expression in lipopolysaccharide- stimulated B cell cultures. J. Immunol. 144:952-59
168. Kim PH, Kagnoff MF. 1990. Transforming growth factor beta 1 increases IgA isotype switching at the clonal level. J. Immunol. 145:3773-78
169. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. 1992. Interleukin 10 and transforming growth factor β cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J. Exp. Med. 175:671-82
170. van Vlasselaer P, Punnonen J, de Vries JE. 1992. Transforming growth factor-β directs IgA switching in human B cells. J. Immunol. 148:2062-67
171. McIntyre TM, Klinman DR, Rothman P, Lugo M, Dasch JR, et al. 1993. Transforming growth factor β1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J. Exp. Med. 177:1031-37
172. Fagarasan S, Honjo T. 2003. Intestinal IgA synthesis: regulation of front-line body defences. Nat. Rev. Immunol. 3:63-72
173. McIntyre TM, Kehry MR, Snapper CM. 1995. Novel in vitro model for high-rate IgA class switching. J. Immunol. 154:3156-61
174. α gene. J. Immunol. 147:4374-83
175. Lin YC, Stavnezer J. 1992. Regulation of transcription of the germ-line Ig α constant region gene by an ATF element and by novel transforming growth factor-α 1-responsive elements. J. Immunol. 149:2914-25
176. Shi MJ, Stavnezer J. 1998. CBF α3 (AML2) is induced by TGF-β1 to bind and activate the mouse germline Ig α promoter. J. Immunol. 161:6751-60
177. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, et al. 1999. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cα promoter. J. Biol. Chem. 274:31577-82
178. Pardali E, Xie XQ, Tsapogas P, Itoh S, Arvanitidis K, et al. 2000. Smad and AML proteins synergistically confer transforming growth factor β1 responsiveness to human germ-line IgA genes. J. Biol. Chem. 275:3552-60
179. Park SR, Lee JH, Kim PH. 2001. Smad3 and Smad4 mediate transforming growth factor-β1-induced IgA expression in murine B lymphocytes. Eur. J. Immunol. 31:1706-15
180. Park SR, Lee EK, Kim BC, Kim PH. 2003. p300 cooperates with Smad3/4 and Runx3 in TGFβ1-induced IgA isotype expression. Eur. J. Immunol. 33:3386-92
181. Borsutzky S, Cazac BB, Roes J, Guzman CA. 2004. TGF-β receptor signaling is critical for mucosal IgA responses. J. Immunol. 173:3305-9
182. van Ginkel FW, Wahl SM, Kearney JF, Kweon MN, Fujihashi K, et al. 1999. Partial IgA-deficiency with increased Th2-type cytokines in TGF-β1 knockout mice. J. Immunol. 163:1951-57
183. Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB. 1994. Maternal rescue of transforming growth factor-β1 null mice. Science 264:1936-38
184. Holder MJ, Knox K, Gordon J. 1992. Factors modifying survival pathways of germinal center B cells. Glucocorticoids and transforming growth factor-β, but not cyclosporin A or anti-CD 19, block surface immunoglobulin-mediated rescue from apoptosis. Eur. J. Immunol. 22:2725-28
185. Lomo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. 1995. TGF-β1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J. Immunol. 154:1634-43
186. Arsura M, Wu M, Sonenshein GE. 1996. TGF β1 inhibits NF-κB/Rel activity inducing apoptosis of B cells: transcriptional activation of IκBα. Immunity 5:31-40
187. Wildey GM, Paul S, Howe PH. 2003. Smad3 potentiates transforming growth factor β (TGFβ)-induced apoptosis and expression of the BH3-only protein Bim in WEHI 231 B lymphocytes. J. Biol. Chem. 278:18069-77
188. Hayakawa K, Asano M, Shinton SA, Gui M, Allman D, et al. 1999. Positive selection of natural autoreactive B cells. Science 285:113-16
189. Lam KP, Rajewsky K. 1999. B cell antigen receptor specificity and surface density together determine B-1 versus B-2 cell development. J. Exp. Med. 190:471-77
190. Snapper CM, Waegell W, Beernink H, Dasch JR. 1993. Transforming growth factor-β1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro. J. Immunol. 151:4625-36
191. Zan H, Cerutti A, Dramitinos P, Schaffer A, Casali P. 1998. CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-β: evidence for TGF-β but not IL-10-dependent direct Sμ → Sα and sequential Sμ → Sγ, Sγ → Sα DNA recombination. J. Immunol. 161:5217-25
192. Caver TE, O'Sullivan FX, Gold LI, Gresham HD. 1996. Intracellular demonstration of active TGFβ1 in B cells and plasma cells of autoimmune mice. IgG-bound TGFβ1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J. Clin. Invest. 98:2496-506
193. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17:189-220
194. Hamerman JA, Ogasawara K, Lanier LL. 2005. NK cells in innate immunity. Curr. Opin. Immunol. 17:29-35
195. H1 priming. Nat. Immunol. 5:1260-65
196. Perussia B, Chan SH, D'Andrea A, Tsuji K, Santoli D, et al. 1992. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J. Immunol. 149:3495-502
197. Tripp CS, Wolf SF, Unanue ER. 1993. Interleukin 12 and tumor necrosis factor α are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc. Natl. Acad. Sci. USA 90:3725-29
198. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, et al. 1986. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136:3916-20
199. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. 1995. Regulation of NK cell functions by TGF-β 1. J. Immunol. 155:1066-73
200. Hunter CA, Bermudez L, Beernink H, Waegell W, Remington JS. 1995. Transforming growth factor-β inhibits interleukin-12-induced production of interferon-γ by natural killer cells: a role for transforming growth factor-γ in the regulation of T cell-independent resistance to Toxoplasma gondii. Eur. J. Immunol. 25:994-1000
201. Su HC, Ishikawa R, Biron CA. 1993. Transforming growth factor-β expression and natural killer cell responses during virus infection of normal, nude, and SCID mice. J. Immunol. 151:4874-90
202. Ortaldo JR, Mason AT, O'Shea JJ, Smyth MJ, Falk LA, et al. 1991. Mechanistic studies of transforming growth factor-β inhibition of IL-2-dependent activation of CD3-large granular lymphocyte functions. Regulation of IL-2R β (p75) signal transduction. J. Immunol. 146:3791-98
203. Malygin AM, Men S, Timonen T. 1993. Regulation of natural killer cell activity by transforming growth factor-β and prostaglandin E2. Scand. J. Immunol. 37:71-76
204. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. 2000. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 21:228-34
205. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-29
206. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, et al. 2003. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100:4120-25
207. Lee JC, Lee KM, Kim DW, Heo DS. 2004. Elevated TGF-β1 secretion and down-modulation of NKG2 D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172:7335-40
208. + T cells, IL-2, and NK cell-derived TGF-β: contrasting effects of anti-CD2 and anti-CD3. J. Immunol. 160:2248-54
209. Steinman RM, Hawiger D, Nussenzweig MC. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685-711
210. Strobl H, Knapp W. 1999. TGF-β1 regulation of dendritic cells. Microbes Infect. 1:1283-90
211. + hemopoietic progenitors. J. Immunol. 157:1499-507
212. Geissmann F, Prost C, Monnet JP, Dy M, Brousse N, Hermine O. 1998. Transforming growth factor β1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J. Exp. Med. 187:961-66
213. + precursor cells develop into Langerhans cells in a TGF-β1-dependent manner. J. Immunol. 163:4869-77
214. Zhang Y, Zhang YY, Ogata M, Chen P, Harada A, et al. 1999. Transforming growth factor-β1 polarizes murine hematopoietic progenitor cells to generate Langerhans cell-like dendritic cells through a monocyte/macrophage differentiation pathway. Blood 93:1208-20
215. Riedl E, Strobl H, Majdic O, Knapp W. 1997. TGF-β1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J. Immunol. 158:1591-97
216. Borkowski TA, Letterio JJ, Farr AG, Udey MC. 1996. A role for endogenous transforming growth factor β1 in Langerhans cell biology: the skin of transforming growth factor β1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 184:2417-22
217. Borkowski TA, Letterio JJ, Mackall CL, Saitoh A, Wang XJ, et al. 1997. A role for TGFβ1 in Langerhans cell biology. Further characterization of the epidermal Langerhans cell defect in TGFβ1 null mice. J. Clin. Invest. 100:575-81
218. -/- SCID mice: paracrine and autocrine effects of transforming growth factor-β1 and -β2(1). J. Invest. Dermatol. 117:1574-80
219. Hacker C, Kirsch RD, Ju XS, Hieronymus T, Gust TC, et al. 2003. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol. 4:380-86
220. Strobl H, Bello-Fernandez C, Riedl E, Pickl WF, Majdic O, et al. 1997. flt3 ligand in cooperation with transforming growth factor-β1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90:1425-34
221. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, et al. 1999. TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162:4567-75
222. Ronger-Savle S, Valladeau J, Claudy A, Schmitt D, Peguet-Navarro J, et al. 2005. TGFβ inhibits CD1d expression on dendritic cells. J. Invest. Dermatol. 124:116-18
223. Yamaguchi Y, Tsumura H, Miwa M, Inaba K. 1997. Contrasting effects of TGF-β1 and TNF-α on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15:144-53
224. Dong Y, Tang L, Letterio JJ, Benveniste EN. 2001. The Smad3 protein is involved in TGF-β inhibition of class II transactivator and class II MHC expression. J. Immunol. 167:311-19
225. Tada Y, Asahina A, Fujita H, Mitsui H, Torii H, et al. 2004. Differential effects of LPS and TGF-β on the production of IL-6 and IL-12 by Langerhans cells, splenic dendritic cells, and macrophages. Cytokine 25:155-61
226. Gruschwitz MS, Hornstein OP. 1992. Expression of transforming growth factor type β on human epidermal dendritic cells. J. Invest. Dermatol. 99:114-16
227. de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, et al. 1998. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J. Immunol. 160:1666-76
228. Morelli AE, Zahorchak AF, Larregina AT, Colvin BL, Logar AJ, et al. 2001. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 98:1512-23
229. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, et al. 2003. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. NY Acad. Sci. 987:15-25
230. Gregory CD, Devitt A. 2004. The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically: Immunology 113:1-14
231. Ashcroft GS. 1999. Bidirectional regulation of macrophage function by TGF-β. Microbes Infect. 1:1275-82
232. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, et al. 1987. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. USA 84:5788-92
233. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. 1988. Transforming growth factor-β (TGF β) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem. Biophys. Res. Commun. 157:793-800
234. Allen JB, Manthey CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM. 1990. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor β. J. Exp. Med. 171:231-47
235. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. 1993. Transforming growth factor β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc. Natl. Acad. Sci. USA 90:4577-81
236. Bauvois B, Rouillard D, Sanceau J, Wietzerbin J. 1992. IFN-γ and transforming growth factor-β1 differently regulate fibronectin and laminin receptors of human differentiating monocytic cells. J. Immunol. 148:3912-19
237. Turner M, Chantry D, Feldmann M. 1990. Transforming growth factor β induces the production of interleukin 6 by human peripheral blood mononuclear cells. Cytokine 2:211-16
238. Riddick CA, Serio KJ, Hodulik CR, Ring WL, Regan MS, Bigby TD. 1999. TGF-β increases leukotriene C4 synthase expression in the monocyte-like cell line, THP-1. J. Immunol. 162:1101-7
239. Bottalico LA, Wager RE, Agellon LB, Assoian RK, Tabas I. 1991. Transforming growth factor-β1 inhibits scavenger receptor activity in THP-1 human macrophages. J. Biol. Chem. 266:22866-71
240. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM Jr, Nicholson AC. 2000. Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ. J. Biol. Chem. 275:1241-46
241. Tridandapani S, Wardrop R, Baran CP, Wang Y, Opalek JM, et al. 2003. TGF-β1 suppresses [correction of supresses] myeloid Fey receptor function by regulating the expression and function of the common γ-subunit. J. Immunol. 170:4572-77
242. Bogdan C, Paik J, Vodovotz Y, Nathan C. 1992. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J. Biol. Chem. 267:23301-8
243. Werner F, Jain MK, Feinberg MW, Sibinga NE, Pellacani A, et al. 2000. Transforming growth factor-β1 inhibition of macrophage activation is mediated via Smad3. J. Biol. Chem. 275:36653-58
244. Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C. 1993. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J. Exp. Med. 178:605-13
245. Tsunawaki S, Sporn M, Ding A, Nathan C. 1988. Deactivation of macrophages by transforming growth factor-β. Nature 334:260-62
246. Janeway CA Jr, Medzhitov R. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197-216
247. Imai K, Takeshita A, Hanazawa S. 2000. Transforming growth factor-β inhibits lipopolysaccharide-stimulated expression of inflammatory cytokines in mouse macrophages through downregulation of activation protein 1 and CD14 receptor expression. Infect. Immun. 68:2418-23
248. Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, Arditi M. 2005. Transforming growth factor-β differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J. Biol. Chem. 280:5491-95
249. Nandan D, Reiner NE. 1997. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action. J. Immunol. 158:1095-101
250. Takeuchi M, Alard P, Streilein JW. 1998. TGF-β promotes immune deviation by altering accessory signals of antigen-presenting cells. J. Immunol. 160:1589-97
251. Du C, Sriram S. 1998. Mechanism of inhibition of LPS-induced IL-12p40 production by IL-10 and TGF-β in ANA-1 cells. J. Leukoc. Biol. 64:92-97
252. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101:890-98
253. McDonald PP, Fadok VA, Bratton D, Henson PM. 1999. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-β in macrophages that have ingested apoptotic cells. J. Immunol. 163:6164-72
254. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. 1992. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148:2207-16
255. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. 2000. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405:85-90
256. Huynh ML, Fadok VA, Henson PM. 2002. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J. Clin. Invest. 109:41-50
257. Otsuka M, Tsuchiya S, Aramaki Y. 2004. Involvement of ERK, a MAP kinase, in the production of TGF-β by macrophages treated with liposomes composed of phosphatidylserine. Biochem. Biophys. Res. Commun. 324:1400-5
258. Pilette C, Ouadrhiri Y, Van Snick J, Renauld JC, Staquet P, et al. 2002. IL-9 inhibits oxidative burst and TNF-α, release in lipopolysaccharide- stimulated human monocytes through TGF-β. J. Immunol. 168:4103-11
259. Bastos KR, Alvarez JM, Marinho CR, Rizzo LV, Lima MR. 2002. Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J. Leukoc. Biol. 71:271-78
260. Gruber BL, Marchese MJ, Kew RR. 1994. Transforming growth factor-β1 mediates mast cell chemotaxis. J. Immunol. 152:5860-67
261. Olsson N, Piek E, ten Dijke P, Nilsson G. 2000. Human mast cell migration in response to members of the transforming growth factor-β family. J. Leukoc. Biol. 67:350-56
262. 7 J. Immunol. 169:5689-95
263. Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, et al. 2005. TGF-β1 inhibits mast cell FcεRI expression. J. Immunol. 174:5987-93
264. Mesples B, Fontaine RH, Lelievre V, Launay JM, Gressens P. 2005. Neuronal TGF-β1 mediates IL-9/mast cell interaction and exacerbates excitotoxicity in newborn mice. Neurobiol. Dis. 18:193-205
265. Bissonnette EY, Enciso JA, Befus AD. 1997. TGF-β1 inhibits the release of histamine and tumor necrosis factor-α from mast cells through an autocrine pathway. Am. J. Respir. Cell Mol. Biol. 16:275-82
266. Gebhardt T, Lorentz A, Detmer F, Trautwein C, Bektas H, et al. 2005. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor β1. Gut 54:928-34
267. Broide DH, Wasserman SI, Alvaro-Gracia J, Zvaifler NJ, Firestein GS. 1989. Transforming growth factor-β1 selectively inhibits IL-3-dependent mast cell proliferation without affecting mast cell function or differentiation. J. Immunol. 143:1591-97
268. Miller HR, Wright SH, Knight PA, Thornton EM. 1999. A novel function for transforming growth factor-β1: upregulation of the expression and the IgE-independent extracellular release of a mucosal mast cell granule-specific β-chymase, mouse mast cell protease-1. Blood 93:3473-86
269. Pennington DW, Lopez AR, Thomas PS, Peck C, Gold WM. 1992. Dog mastocytoma cells produce transforming growth factor β1. J. Clin. Invest. 90:35-41
270. Gordon JR, Galli SJ. 1994. Promotion of mouse fibroblast collagen gene expression by mast cells stimulated via the FcεRI. Role for mast cell-derived transforming growth factor β and tumor necrosis factor α. J. Exp. Med. 180:2027-37
271. Lindstedt KA, Wang Y, Shiota N, Saarinen J, Hyytiainen M, et al. 2001. Activation of paracrine TGF-β1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J. 15:1377-88
272. Kobayashi SD, Voyich JM, DeLeo FR. 2003. Regulation of the neutrophil-mediated inflammatory response to infection. Microbes Infect. 5:1337-44
273. Klion AD, Nutman TB. 2004. The role of eosinophils in host defense against helminth parasites. J. Allergy Clin. Immunol. 113:30-37
274. Munitz A, Levi-Schaffer F. 2004. Eosinophils: 'new' roles for Old' cells. Allergy 59:268-75
275. Reibman J, Meixler S, Lee TC, Gold LI, Cronstein BN, et al. 1991. Transforming growth factor β1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc. Natl. Acad. Sci. USA 88:6805-9
276. Brandes ME, Mai UE, Ohura K, Wahl SM. 1991. Type I transforming growth factor-β receptors on neutrophils mediate chemotaxis to transforming growth factor-β. J. Immunol. 147:1600-6
277. Chen CC, Manning AM. 1996. TGF-β1, IL-10 and IL-4 differentially modulate the cytokine-induced expression of IL-6 and IL-8 in human endothelial cells. Cytokine 8:58-65
278. 1 down-regulates inflammatory cytokine-induced VCAM-1 expression in cultured human glomerular endothelial cells. Nephrol. Dial. Transplant. 15:596-604
279. Smith WB, Noack L, Khew-Goodall Y, Isenmann S, Vadas MA, Gamble JR. 1996. Transforming growth factor-β1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J. Immunol. 157:360-68
280. Luttmann W, Franz P, Matthys H, Virchow JC Jr. 1998. Effects of TGF-β on eosinophil chemotaxis. Scand. J. Immunol. 47:127-30
281. Lagraoui M, Gagnon L. 1997. Enhancement of human neutrophil survival and activation by TGF-β1. Cell Mol. Biol. 43:313-18
282. Balazovich KJ, Fernandez R, Hinkovska-Galcheva V, Suchard SJ, Boxer LA. 1996. Transforming growth factor-β1 stimulates degranulation and oxidant release by adherent human neutrophils. J. Leukoc. Biol. 60:772-77
283. Myrtek D, Knoll M, Matthiesen T, Krause S, Lohrmann J, et al. 2004. Expression of interleukin-13 receptor alpha 1-subunit on peripheral blood eosinophils is regulated by cytokines. Immunology 112:597-604
284. Alam R, Forsythe P, Stafford S, Fukuda Y. 1994. Transforming growth factor β abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J. Exp. Med. 179:1041-45
285. Fava RA, Olsen NJ, Postlethwaite AE, Broadley KN, Davidson JM, et al. 1991. Transforming growth factor β1 (TGF-β1) induced neutrophil recruitment to synovial tissues: implications for TGF-β-driven synovial inflammation and hyperplasia. J. Exp. Med. 173:1121-32
286. Kobayashi T, Iijima K, Kita H. 2003. Marked airway eosinophilia prevents development of airway hyper-responsiveness during an allergic response in IL-5 transgenic mice. J. Immunol. 170:5756-63
287. Tanaka H, Komai M, Nagao K, Ishizaki M, Kajiwara D, et al. 2004. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am. J. Respir. Cell Mol. Biol. 31:62-68
288. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, et al. 2004. Inhibition of airway remodeling in IL-5-deficient mice. J. Clin. Invest. 113:551-60
289. Prud'homme GJ, Piccirillo CA. 2000. The inhibitory effects of transforming growth factor-β-1 (TGF-β1) in autoimmune diseases. J. Autoimmun. 14:23-42
290. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, et al. 1995. SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-β knockout mice. J. Immunol. 155:3205-12
291. Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, et al. 1996. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse. Blood 87:1439-45
292. Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. 1998. Decreased production of TGF-β by lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 160:2539-45
293. Ohtsuka K, Gray JD, Stimmler MM, Horwitz DA. 1999. The relationship between defects in lymphocyte production of transforming growth factor-β1 in systemic lupus erythematosus and disease activity or severity. Lupus 8:90-94
294. Lowrance JH, O'Sullivan FX, Caver TE, Waegell W, Gresham HD. 1994. Spontaneous elaboration of transforming growth factor β suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J. Exp. Med. 180:1693-703
295. Raz E, Dudler J, Lotz M, Baird SM, Berry CC, et al. 1995. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 4:286-92
296. Holmdahl R, Bockermann R, Backlund J, Yamada H. 2002. The molecular pathogenesis of collagen-induced arthritis in mice-a model for rheumatoid arthritis. Ageing Res. Rev. 1:135-47
297. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. 1992. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89:7375-79
298. Wahl SM, Allen JB, Costa GL, Wong HL, Dasch JR. 1993. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor β. J. Exp. Med. 177:225-30
299. Schramm C, Kriegsmann J, Protschka M, Huber S, Hansen T, et al. 2004. Susceptibility to collagen-induced arthritis is modulated by TGFβ responsiveness of T cells. Arthritis Res. Ther. 6:R114-19
300. King C, Davies J, Mueller R, Lee MS, Krahl T, et al. 1998. TGF-β1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 8:601-13
301. Grewal IS, Grewal KD, Wong FS, Wang H, Picarella DE, et al. 2002. Expression of transgene encoded TGF-β in islets prevents autoimmune diabetes in NOD mice by a local mechanism. J. Autoimmun. 19:9-22
302. Moritani M, Yoshimoto K, Wong SF, Tanaka C, Yamaoka T, et al. 1998. Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-β1. J. Clin. Invest. 102:499-506
303. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. 2003. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9:1202-8
304. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346:1692-98
305. Johns LD, Flanders KC, Ranges GE, Sriram S. 1991. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. J. Immunol. 147:1792-96
306. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. 1991. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J. Immunol. 146:3012-17
307. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ. 1991. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. USA 88:2918-21
308. Racke MK, Cannella B, Albert P, Sporn M, Raine CS, McFarlin DE. 1992. Evidence of endogenous regulatory function of transforming growth factor-α1 in experimental allergic encephalomyelitis. Int. Immunol. 4:615-20
309. Issazadeh S, Mustafa M, Ljungdahl A, Hojeberg B, Dagerlind A, et al. 1995. Interferon γ, interleukin 4 and transforming growth factor β in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J. Neurosci. Res. 40:579-90
310. Johns LD, Sriram S. 1993. Experimental allergic encephalomyelitis: neutralizing antibody to TGF β1 enhances the clinical severity of the disease. J. Neuroimmunol. 47:1-7
311. Bai XF, Shi FD, Xiao BG, Li HL, van der Meide PH, Link H. 1997. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA. J. Neuroimmunol. 80:65-75
312. Nowell PC. 1976. The clonal evolution of tumor cell populations. Science 194:23-28
313. Foulds L. 1954. The experimental study of tumor progression: a review. Cancer Res. 14:327-39
314. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-70
315. Weinberg RA. 1996. How cancer arises. Sci. Am. 275:62-70
316. Pardoll D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21:807-39
317. Dunn GP, Old LJ, Schreiber RD. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-60
318. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. 1993. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 53:4391-98
319. Stander M, Naumann U, Dumitrescu L, Heneka M, Loschmann P, et al. 1998. Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 5:1187-94
320. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, et al. 1996. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA 93:2909-14
321. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, et al. 2004. RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64:7596-603
322. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, et al. 1990. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87:1486-90
323. + regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102:9253-57
324. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-18
325. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59:3128-33
326. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-32
327. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, et al. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl. Acad. Sci. USA 102:419-24
328. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. 2005. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65:2457-64
329. + CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106:2018-25
330. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352:1685-95
331. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, et al. 2002. Innate and acquired immunity in atherogenesis. Nat. Med, 8:1218-26
332. Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-74
333. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, et al. 2001. Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89:930-34
334. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, et al. 2002. Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22:975-82
335. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. 2003. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112:1342-50
336. Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, et al. 2003. Specific abrogation of transforming growth factor-β signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 102:4052-58
337. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, et al. 2001. Transforming growth factor-β1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler. Thromb. Vasc. Biol. 21:2011-18
338. Amento EP, Ehsani N, Palmer H, Libby P. 1991. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. 11:1223-30
339. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. 1996. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem. J. 315(Pt. 1):335-42
340. Cipollone F, Fazia M, Mincione G, Iezzi A, Pini B, et al. 2004. Increased expression of transforming growth factor-β1 as a stabilizing factor in human atherosclerotic plaques. Stroke 35:2253-57
341. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, et al. 1995. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat. Med. 1:74-79
342. + T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation. J. Clin. Invest. 105:61-70
343. Scherf W, Burdach S, Hansen G. 2005. Reduced expression of transforming growth factor β1 exacerbates pathology in an experimental asthma model. Eur. J. Immunol. 35:198-206
344. Redington AE, Madden J, Frew AJ, Djukanovic R, Roche WR, et al. 1997. Transforming growth factor-β1 in asthma. Measurement in bronchoalveolar lavage fluid. Am. J. Respir. Crit. Care Med. 156:642-47
345. Branton MH, Kopp JB. 1999. TGF-β and fibrosis. Microbes Infect. 1:1349-65
346. Bouma G, Strober W. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521-33
347. Monteleone G, Pallone F, MacDonald TT. 2004. Smad7 in TGF-β-mediated negative regulation of gut inflammation. Trends Immunol. 25:513-17
348. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. 2001. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108:601-9
349. Ming M, Ewen ME, Pereira ME. 1995. Trypanosome invasion of mammalian cells requires activation of the TGF β signaling pathway. Cell 82:287-96
350. Silva JS, Twardzik DR, Reed SG. 1991. Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor β (TGF-β). J. Exp. Med. 174:539-45
351. Hansen DS, Villacres-Eriksson M, Akerblom L, Hellman U, Segura E, et al. 1998. An immunoaffinity-purified Trypanosoma cruzi antigen suppresses cellular proliferation through a TGF-β-mediated mechanism. Scand. J. Immunol. 47:509-16
352. Olsson T, Bakhiet M, Hojeberg B, Ljungdahl A, Edlund C, et al. 1993. CD8 is critically involved in lymphocyte activation by a T. brucei brucei-released molecule. Cell 72:715-27
353. Sacks D, Noben-Trauth N. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845-58
354. Scott P. 1991. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147:3149-55
355. Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA. 1989. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:266-74
356. Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG. 1993. Transforming growth factor β as a virulence mechanism for Leishmania braziliensis. Proc. Natl. Acad. Sci. USA 90:3442-46
357. Gantt KR, Schultz-Cherry S, Rodriguez N, Jeronimo SM, Nascimento ET, et al. 2003. Activation of TGF-κ by Leishmania chagasi: importance for parasite survival in macrophages. J. Immunol. 170:2613-20
358. Langermans JA, Nibbering PH, Van Vuren-Van Der Hulst ME, Van Furth R. 2001. Transforming growth factor-β suppresses interferon-γ-induced toxoplasmastatic activity in murine macrophages by inhibition of tumour necrosis factor-α production. Parasite Immunol. 23:169-75
359. Bermudez LE, Covaro G, Remington J. 1993. Infection of murine macrophages with Toxoplasma gondii is associated with release of transforming growth factor β and downregulation of expression of tumor necrosis factor receptors. Infect. Immun. 61:4126-30
360. Omer FM, Kurtzhals JA, Riley EM. 2000. Maintaining the immunological balance in parasitic infections: a role for TGF-β? Parasitol. Today 16:18-23
361. Omer FM, Riley EM. 1998. Transforming growth factor β production is inversely correlated with severity of murine malaria infection. J. Exp. Med. 188:39-48
362. Li C, Corraliza I, Langhorne J. 1999. A defect in interleukin-10 leads to enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice. Infect. Immun. 67:4435-42
363. Li C, Sanni LA, Omer F, Riley E, Langhorne J. 2003. Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by antitumor necrosis factor α and exacerbated by anti-transforming growth factor β antibodies. Infect. Immun. 71:4850-56
364. Omer FM, de Souza JB, Corran PH, Sultan AA, Riley EM. 2003. Activation of transforming growth factor β by malaria parasite-derived metalloproteinases and a thrombospondin-like molecule. J. Exp. Med. 198:1817-27
365. Toossi Z, Young TG, Averill LE, Hamilton BD, Shiratsuchi H, Ellner JJ. 1995. Induction of transforming growth factor β1 by purified protein derivative of Mycobacterium tuberculosis. Infect. Immun. 63:224-28
366. Dahl KE, Shiratsuchi H, Hamilton BD, Ellner JJ, Toossi Z. 1996. Selective induction of transforming growth factor β in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infect. Immun. 64:399-405
367. Pamer EG. 2004. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4:812-23
368. Nakane A, Asano M, Sasaki S, Nishikawa S, Miura T, et al. 1996. Transforming growth factor β is protective in host resistance against Listeria monocytogenes infection in mice. Infect. Immun. 64:3901-4
369. Spaccapelo R, Romani L, Tonnetti L, Cenci E, Mencacci A, et al. 1995. TGF-β is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J. Immunol. 155:1349-60
370. Letterio JJ, Lehrnbecher T, Pollack G, Walsh TJ, Chanock SJ. 2001. Invasive candidiasis stimulates hepatocyte and monocyte production of active transforming growth factor β. Infect. Immun. 69:5115-20
371. Schultz-Cherry S, Hinshaw VS. 1996. Influenza virus neuraminidase activates latent transforming growth factor β. J. Virol. 70:8624-29
372. Cecere A, Marotta F, Vangieri B, Tancredi L, Gattoni A. 2004. Progressive liver injury in chronic hepatitis C infection is related to altered cellular immune response and to different citokine profile. Panminerva Med. 46:171-87
373. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, et al. 2004. Hepatitis C virus core protein upregulates transforming growth factor-β1 transcription. J. Med. Virol. 72:52-59
374. Cheng PL, Chang MH, Chao CH, Lee YH. 2004. Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-β/Smad3-mediated transcriptional activation. Oncogens 23:7821-38
375. Reinhold D, Wrenger S, Kahne T, Ansorge S. 1999. HIV-1 Tat: immunosuppression via TGF-β1 induction. Immunol. Today 20:384-85
376. Chen S, Tuttle DL, Oshier JT, Knot HJ, Streit WJ, et al. 2005. Transforming growth factor-β1 increases CXCR4 expression, stromal-derived factor-1 α-stimulated signalling and human immunodeficiency virus-1 entry in human monocyte-derived macrophages. Immunology 114:565-74
377. Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, et al. 2005. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307:81621-25